---
schema_version: "secwatch.filing_event.v1"
accession: "0001679363-24-000029"
form_type: "8-K"
ticker: null
cik: "0001679363"
company_name: "Morphic Holding, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T08:05:16.856892+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Morphic Q1 net loss $45.3M ($0.91/sh); EMERALD-2 enrollment on track; CMO appointed

## Summary
- Net loss of $45.3M ($0.91/sh) vs. $36.1M ($0.90/sh) in Q1 2023; R&D expense $42.4M (up 39%).
- Cash, equivalents, and marketable securities $658.8M; cash runway into H2 2027.
- EMERALD-2 Phase 2b trial in UC enrollment on track; primary endpoint readout expected H1 2025.
- First patient dosing in GARNET Phase 2 Crohn's study expected Q2 2024.
- Appointed Dr. Simon Cooper as CMO; he previously developed risankizumab at AbbVie for UC and CD.

## SEC filing metadata
- accession: 0001679363-24-000029
- form_type: 8-K
- cik: 0001679363
- company_name: Morphic Holding, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/0001679363-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/morf-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001679363-24-000029
- JSON: https://secwatch.observer/filing/0001679363-24-000029.json
- Plain text: https://secwatch.observer/filing/0001679363-24-000029.txt

## Key facts
- Earnings Releases
  Morphic Holding, Inc. reported the first quarter 2024 results: net income Net loss for the quarter ended March 31, 2024, was $45.3 million or $0.91 per share, EPS $0.91 per share.
  - Period: the first quarter 2024
  - Net income: Net loss for the quarter ended March 31, 2024, was $45.3 million or $0.91 per share
  - EPS: $0.91 per share
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2024, was $45.3 million or $0.91 per share compared to net loss of $36.1 million or $0.90 per share for the same quarter last year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1679363/000167936324000029/0001679363-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.